Ustekinumab for Refractory Giant Cell Arteritis: A Prospective 52-week Trial ☆

Giant cell arteritis (GCA) is the most common form of systemic vasculitis. Glucocorticoids are an effective treatment but have significant adverse events and relapses are common. Interleukins 12 (IL-12) and 23 (IL-23) stimulate TH1 and TH17 responses and are i implicated in the pathogenesis of GCA. The aim of this study was to evaluate the efficacy and safety of IL-12/23 blockade with ustekinumab in GCA.

Source: Seminars in Arthritis and Rheumatism - April 21, 2018 Category: Rheumatology Authors: Richard Conway, Lorraine O ’Neill, Phil Gallagher, Geraldine M McCarthy, Conor C Murphy, Douglas J Veale, Ursula Fearon, Eamonn S Molloy Source Type: research